The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: The OCEAN study

Journal of Bone and Mineral Research

Volumn 29, Issue 3, 2014, Pages 629-638

  Engelke, Klaus ^a,b   Nagase, Shinichi ^c   Fuerst, Thomas ^d   Small, Maria ^c   Kuwayama, Tomohiro ^c   Deacon, Stephen ^c   Eastell, Richard ^e   Genant, Harry K ^f  

^a Synarc Inc   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c ONO PHARMACEUTICAL CO   (Japan)

^d SYNARC INC   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cathepsin K inhibitor; DXA; proximal femur; QCT; spine

Indexed keywords

CATHEPSIN K INHIBITOR; DXA; PROXIMAL FEMUR; QCT; SPINE;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; CATHEPSIN K; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; THIAZOLIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84894435615     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2080     Document Type: Article

References (19)

1. Berti PJ, Storer AC., Alignment/phylogeny of the papain superfamily of cysteine proteases. J Mol Biol. 1995; 246 (2): 273-83.
2. Gelb BD, Shi GP, Chapman HA, Desnick RJ., Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996; 273 (5279): 1236-8.
3. Yamada H, Mori H, Kunishige A, et al., Efficacy of ONO-5334, a cathepsin K inhibitor, on bone mass and strength in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2010; 25 (Suppl 1):[Poster session presented at: American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting; 2010 Oct 15-19; Toronto, ON, Canada; Presentation Number: FR0438]. Available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= a0378fcb-7946-44a5-bc98-c4145052682f.
4. Nagase S, Ohyama M, Hashimoto Y, Small M, Kuwayama T, Deacon S., Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, Phase 1 study. J Clin Pharmacol. 2012; 52 (3): 306-18.
5. Eastell R, Nagase S, Ohyama M, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res. 2011; 26 (6): 1303-12.
6. Eastell R, Nagase S, Small M, et al. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res. Epub. 2013 Jul 22: DOI: 10.1002/jbmr.2047
7. Rand T, Seidl G, Kainberger F, et al. Impact of spinal degenerative changes on the evaluation of bone mineral density with dual energy X-ray absorptiometry (DXA). Calcif Tissue Int. 1997; 60 (5): 430-3.
8. Barden HS, Markwardt P, Payne R, Hawkins B, Frank M, Faulkner KG., Automated assessment of exclusion criteria for DXA lumbar spine scans. J Clin Densitom. 2003; 6 (4): 401-10.
9. Bauman WA, Schwartz E, Song IS, et al. Dual-energy X-ray absorptiometry overestimates bone mineral density of the lumbar spine in persons with spinal cord injury. Spinal Cord. 2009; 47 (8): 628-33.
10. Patel R, Blake GM, Rymer J, Fogelman I., Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int. 2000; 11 (1): 68-75.
11. Celik O, Salci Y, Manisali M, Korkusuz F., The effect of hip rotation on bone mineral density of the proximal femur measured by dual energy X-ray absorptiometry. Eklem Hastalik Cerrahisi. 2009; 20 (2): 71-7.
12. Goh JC, Low SL, Bose K., Effect of femoral rotation on bone mineral density measurements with dual energy X-ray absorptiometry. Calcif Tissue Int. 1995; 57 (5): 340-3.
13. Kang Y, Engelke K, Kalender WA., A new accurate and precise 3-D segmentation method for skeletal structures in volumetric CT data. IEEE Trans Med Imaging. 2003; 22 (5): 586-98.
14. Mastmeyer A, Engelke K, Fuchs C, Kalender WA., A hierarchical 3D segmentation method and the definition of vertebral body coordinate systems for QCT of the lumbar spine. Med Image Anal. 2006; 10 (4): 560-77.
15. Lewiecki EM, Keaveny TM, Kopperdahl DL, et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2009; 94 (1): 171-80.
16. Eastell R, Lang T, Boonen S, et al. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2010; 21 (7): 1277-85.
17. Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res. 2012 Feb; 27 (2): 255-62.
18. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012; 27 (11): 2251-8.
19. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296 (24): 2927-38.